COMPASS Pathways plc

COMPASS Pathways plc is a clinical-stage biotechnology company focused on developing COMP360, a proprietary pharmaceutical-grade psilocybin treatment for serious mental health conditions. The company is building evidence for psilocybin-assisted therapy in treatment-resistant depression and is positioning itself for eventual commercialization if regulatory approval is achieved. Its model combines drug development with a planned treatment-delivery ecosystem, including training, market access, and potential third-party treatment-site partnerships. To date, it has not generated product revenue and remains dependent on clinical progress and external financing.

0.77

0.77

— COMPASS Pathways plc
%
Investigational therapeutic candidate100% COMP360 psilocybin formulation developed for potential treatment of serious mental health conditions, especially treatment-resistant depression.
Clinical development services0% Late-stage clinical trials, regulatory preparation, and supporting manufacturing work needed to advance COMP360 toward approval.
Commercialization infrastructure0% Planned market access, physician education, and treatment-site enablement capabilities for a future launch.

COMPASS Pathways does not currently sell a commercial product, so its near-term 'customers' are primarily clinical...

  • Clinical trial participantsprimary

    Patients enrolled in COMP360 studies who provide the data needed to prove safety and efficacy.

  • Investigators and treatment sitesprimary

    Hospitals, clinics, and research sites that administer the therapy under protocol and generate clinical evidence.

  • Healthcare professionalsprimary

    Psychiatrists and other clinicians who would need to be trained to identify, prescribe, and supervise COMP360 use after approval.

  • Payors and healthcare systemssecondary

    Insurers and health systems that would influence reimbursement, access, and adoption of a novel mental-health therapy.

  • Commercial partnerssecondary

    Contract sales organizations or commercialization partners that may help launch and distribute the therapy in selected markets.

The company is headquartered in the United States and explicitly plans to build its own market access and...

  • •United States is the core planned commercialization market
  • •North America is the primary target for future market access build-out
  • •Europe matters through data privacy and healthcare regulatory compliance
  • •Third-party treatment-site networks may be used in selected geographies
  • •No revenue by country is disclosed because the company has no product sales yet

COMPASS Pathways is focused on completing late-stage clinical development of COMP360 and generating the evidence needed...

01
Complete Phase 3 COMP005 and COMP006 developmentshort-term

Regulatory approval depends on robust late-stage efficacy and safety data for COMP360 in treatment-resistant depression.

02
Prepare commercialization and market access capabilitiesmedium-term

A novel psilocybin therapy requires trained sites, physician education, and reimbursement planning to convert approval into adoption.

03
Secure external funding and strategic collaborationsshort-term

The company has no product revenue and needs capital to fund development and pre-launch infrastructure.

The company faces the core risk of clinical-stage biotechnology: COMP360 may fail to demonstrate sufficient safety or...

critical

Failure of Phase 3 COMP005/COMP006 trials

The company’s value depends on proving COMP360 is safe and effective in treatment-resistant depression.

Scope
Lead program and primary value driver
Materiality
high
high

Insufficient capital to fund development and launch preparation

The company has no revenue and expects to rely on external financing for the foreseeable future.

Scope
Corporate liquidity and operating runway
Materiality
high
high

Commercialization and market access execution risk

Management has limited experience selling therapeutic substances and may need to build or outsource sales capabilities.

Scope
Future launch in North America and selected geographies
Materiality
high
high

Healthcare regulatory and compliance risk

The business is subject to anti-kickback, privacy, foreign healthcare, and anti-corruption rules that can restrict operations.

Scope
Clinical research, commercialization, and partner relationships
Materiality
medium
high

Psilocybin-specific legal uncertainty

Federal and state laws governing psilocybin and psilocin could limit development, distribution, or commercialization pathways.

Scope
U.S. operations and future product launch
Materiality
high
Warrant liabilities at fair value
Can materially affect quarterly net loss and balance sheet volatility
Research and development expense recognition
Drives operating loss and makes period-to-period comparability difficult
Future collaboration and licensing accounting
Could affect revenue timing, deferred income, and margin profile once monetization begins

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

MapLight Therapeutics, Inc.

MPLT · Pharmaceutical Preparations

RELMADA THERAPEUTICS, INC.

RLMD · Pharmaceutical Preparations

LB PHARMACEUTICALS INC

LBRX · Pharmaceutical Preparations

Praxis Precision Medicines, Inc.

PRAX · Pharmaceutical Preparations

Rapport Therapeutics, Inc.

RAPP · Pharmaceutical Preparations

: 11/08/2026